Fig. 5: Detection rate of the model evaluated on a cohort of healthy donors and donors with late-stage prostate cancer (mCRPC).
From: Circulating tumor cell detection in cancer patients using in-flow deep learning holography
a Distribution of detected CTCs in patient samples, normalized to the volume of whole blood in the initial tube to account for sample variability. b-e CTCs identified in prostate cancer patient samples, with corresponding immunofluorescent (IF) signal f–i. For the two IF channels captured, PSMA served as a prostate-specific marker and EpCAM served as a pan-cancer marker (for epithelial cells).
